Xeris Biopharma | Investor Presentation Deck

Xeris Biopharma | Investor Presentation Deck | 11 slides

Xeris Biopharma · 2022-10

arc beats above · slides in the middle · loops below · scroll → 2 LOOPS

coverage by narrative range · generated from this deck JSON

Narrative range 6 total

Metadata

Components

Metrics

Tools

Frameworks

Beats

Loops

Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits

— 0/1 slides

100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Product 2 slides 100% 2/2 slides 100% 2/2 slides · 8 hits

— 0/2 slides

50% 1/2 slides 50% 1/2 slides 100% 2/2 slides 100% 2/2 slides Solution 2 slides 100% 2/2 slides 100% 2/2 slides · 6 hits

— 0/2 slides

50% 1/2 slides

— 0/2 slides

100% 2/2 slides 100% 2/2 slides Key Takeaways 1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits

— 0/1 slides

100% 1/1 slides 100% 1/1 slides

every slide · same image gating as the playbook

Includes Exhibit 99.2 reference and copyright notice.front_matter

front_matter

other

The slide uses a problem-solution framework to justify the market size for a new delivery method.size_opportunity

Open slide detailBeat · ProblemLoop · Cost Of Inaction

plan_implementation

Open slide detailBeat · ProductLoop · Golden Circle

The slide outlines a clinical trial structure involving two parts, with crossover periods for Part 1.plan_implementation

Open slide detailBeat · ProductLoop · Golden Circle

The chart compares subcutaneous (SC) administration of XP-8121 against oral (PO) administration of Synthroid.analyze_data

Open slide detailBeat · SolutionLoop · Golden Circle

Clinical trial data (XP-8121-108) comparing subcutaneous (SC) vs oral (PO) administration.analyze_data

Open slide detailBeat · SolutionLoop · Golden Circle

The chart shows a comparison of simulated thyroxine concentrations over 7 days.analyze_data